SAR125844 derived from triazolopyridazine is an effective specific c-Met inhibitor with an IC50 value of 4 nM.64 A phase I trial (NCT01657214) of SAR125844 displayed encouraging anti-NSCLC activity in patients with MET amplification, and the drug was well tolerated.65 More than a dozen c-Met inhibitors are currently under clinical assessment in China for the treatment of various malignancies either alone or in combination, such as bozitinib, ningetinib, glumetinib, and kanitinib. The gene discussed is MET; the disease is non-small cell lung carcinoma.